Savara SVRA
NASDAQ SVRA
$4.99 +0.07 (+1.42%)
At close: Nov 11, 2026 · 4:00 PM EST

Savara (SVRA) Gains from Sales and Divestitures (2009 - 2014)

Updated

Analysis

Savara (SVRA) Gains from Sales and Divestitures (2009 - 2014) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Savara 1.09 Bn 407.27 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2014 61,315.00
Sep 30, 2013 161,190.00
Jun 30, 2013 -161,190.00
Mar 31, 2013 61,315.00
Mar 31, 2012 -4,503.00
Mar 31, 2011 2,973.00
Dec 31, 2010 -2,250.00
Sep 30, 2010 -57,535.00
Mar 31, 2010 55,516.00
Mar 31, 2009 279.00
API Access

Savara Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=SVRA&period=max&api_key=YOUR_API_KEY